Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Nov 25 2025

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has announced that it received final approval from the USFDA for Verapamil Hydrochloride Extended-Release Tablets in various strengths. These tablets are intended to help lower high blood pressure and reduce the risk of serious heart issues. The production will take place at Zydus's facility in Baddi, Himachal Pradesh.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 25, 2025, titled "Zydus receives final approval from USFDA for Verapamil Hydrochloride Extended-Release Tablets USP, 120 mg, 180 mg and 240 mg".

Zydus Lifesciences Limited on 6ix

In the deck

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases